Search results for "HDAC"

HDAC inhibitors target oncogenic BRAF and p53 in melanoma cells and promote a switch from pro-survival autophagy to apoptosis

Antitumor effects of novel co-drugs linking histone deacetylase and ribonucleotide reductase inhibitors in hematological tumors

2011

Combination therapy is the mainstay of anticancer therapy due to the significant synergistic effects achievable. Now that anticancer drug research turned toward a more molecular targeted approach, the design of dual-target drugs appears to be a new promising strategy with the potential to improve the therapeutic efficacy of the single drug and to reduce the probability of drug induced resistance and cross resistance. In our previous work, we found that 3’-C-methyl-adenosine (3’-Me-Ado), developed by us as a potent ribonucleotide reductase (RR) inhibitor with antitumor activity against both human leukemia and carcinoma cell lines, elicited significant growth inhibitory and apoptotic synergis…

Loss of the Sin3A/Rpd3 Histone De-Acetylase Complex Causes Telomeric Fusions

2009

Loss of the Sin3A/Rpd3 Histone De-Acetylase Complex Causes Polytene Chromosome Telomeric Fusions

2009

HISTONE DEACETYLASE INHIBITORS SENSITIZE HEPATOMA CELLS TO TRAIL_INDUCED APOPTOSIS

2008

BIOLOGICAL EFFECTS OF JAHA, A NEW HISTONE DEACETYLASE INHIBITOR, ON CANCER CELLS FROM HUMAN BREAST EPITHELIUM

The histone deacetylase inhibitors (HDACis) are a class of chemically heterogeneous anticancer agents of which suberoylanilide hydroxamic acid (SAHA) is a prototypical member. SAHA derivatives may be obtained by the three-dimensional manipulation of the SAHA aryl cap, such as the incorporation of a ferrocene unit like that present in Jay Amin hydroxamic acid (JAHA) and homo-JAHA (Spencer et al., 2011). These metal-based SAHA analogues have been tested for their cytotoxic activity toward triple-negative MDA-MB231 breast cancer cells. The results obtained indicate that of the two compounds tested, only JAHA was prominently active on breast cancer cells with an IC50 of 8.45 μM at 72 h of treat…

Histone Deacetylase Inhibitors in the Treatment of Hematological Malignancies and Solid Tumors

2010

The human genome is epigenetically organized through a series of modifications to the histone proteins that interact with the DNA. In cancer, many of the proteins that regulate these modifications can be altered in both function and expression. One example of this is the family of histone deacetylases (HDACs), which as their name implies remove acetyl groups from the histone proteins, allowing for more condensed nucleosomal structure. HDACs have increased expression in cancer and are also believed to promote carcinogenesis through the acetylation and interaction with key transcriptional regulators. Given this, small molecule histone deacetylases inhibitors have been identified and developed…

The sensitization of HepG2 and HT29 cells to TRAIL-induced apoptosis by histone deacetylase inhibitors is mediated by down-regulation of AKT and NF-k…

2008

A chromatin-associated histone deacetylase from pea (Pisum sativum)

1991

Abstract A histone deacetylase activity has been found in preparation of chromatin from pea (Pisum sativum) embryonic axes. This activity readily deacetylates free histones and is somewhat specific for H2A and H2B; this property and its chromatographic behaviour allowed us to identify the enzyme with the previously described histone deacetylase HD2 (Sendra et al., Plant Mol. Biol., 11 (1988) 857). HD2 is only loosely associated to chromatin but the enzymatic activity is enhanced when chromatin adopts a folded conformation. Polyamines and divalent cations activate the enzyme, probably due to their effect on chromatin folding.

Distinct Site Specificity of Two Pea Histone Deacetylase Complexes

2001

We report on the site specificity of two intact pea histone deacetylase complexes. HD1 deacetylates lysines 5 and 16 of H4 in the order K16 > K5, while in the case of H3 the preferred order is K4 >> K18 approximately K9. The specificity of the HD2 complex is markedly different. The preferred residues in H4 are K8 approximately K5 > K16, while in H3 deacetylation, the complex HD2 prefers sites 4 and 18. To obtain these results, we have used a novel procedure based on the SPOT technique, a method to synthesize peptides on membrane supports. Different sets of membranes with sequentially overlapping histone peptides containing acetylated lysines in the sites corresponding to all in vivo acetyla…